Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a new clinical readout from the ongoing TUPELO Phase 1b/2 trial of REC-4881 in FAP at an upcoming company webinar. The webinar will be held on December 8, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT, and will be streamed live on Recursion’s X, LinkedIn, and YouTube accounts. Webinar title: Ongoing Phase 1b/2 ...

Financial Status & Outlook - Recursion had approximately $785 million in cash as of October 9, 2025 [12, 72] - The company anticipates a cash runway through the end of 2027 without needing additional financing [12, 71] - Recursion projects its 2025 cash burn to be less than $450 million [73] - The company expects its 2026 cash burn to be less than $390 million [73] - Total cash inflows exceeding $500 million have been achieved across all partnerships and collaborations [15, 72] Pipeline & Platform Advancements - The company is anticipating multiple catalysts in the second half of 2025, including additional safety and efficacy data for REC-4881 in Familial Adenomatous Polyposis (FAP) [11, 79] - Recursion's platform has facilitated a $30 million milestone payment for delivering a second whole-genome neuro map [15, 72, 77] - In a Phase 1b/2 trial of REC-4881, 43% median reduction in total polyp burden was observed [61] - 6 out of 6 patients achieved >30% reduction in total polyp burden in REC-4881 Phase 1b/2 trial [62] - In Phase 1 monotherapy dose-escalation of REC-617, 90% of patients experienced treatment-related adverse events (TRAEs), with 28% being Grade ≥3 [48]

Core Insights - ClearBridge Investments reported a strong rebound in U.S. equities during Q2 2025, with the S&P 500 Index returning 10.9% and the Russell 3000 Index advancing 11.0% as risk-on sentiment increased following a pause in tariff implementation [1] - The ClearBridge Select Strategy outperformed its benchmark due to effective portfolio construction across various companies and sectors with distinct growth drivers [1] Company Highlights - Caris Life Sciences, Inc. (NASDAQ:CAI) is highlighted as a key stock in the ClearBridge Select Strategy, being an AI-driven TechBio company focused on cancer care and genetic profiling [2][3] - Caris Life Sciences experienced a one-month return of -12.04% but gained 19.75% over three months, closing at $33.53 per share with a market capitalization of $9.431 billion as of September 17, 2025 [2] - The company went public late in Q2 2025 and offers differentiated molecular profiling services to biopharmaceutical companies using machine learning algorithms [3] Hedge Fund Interest - Caris Life Sciences was held by 42 hedge fund portfolios at the end of Q2 2025, a significant increase from 0 in the previous quarter, indicating growing interest among institutional investors [4] - Despite the potential of Caris Life Sciences, the company is not listed among the 30 most popular stocks among hedge funds, with some analysts suggesting that other AI stocks may offer greater upside potential and less downside risk [4]

Core Insights - Recursion reported a $7 million milestone achievement with Sanofi, reflecting progress in their partnered discovery programs and overall business momentum [3][4][11] - The company is advancing multiple clinical programs, including REC-1245 and REC-617, targeting various cancer indications and leveraging advanced AI models for drug discovery [3][4][5] Business Highlights - **Partnerships**: Recursion has established collaborations with major pharmaceutical companies such as Sanofi, Roche, Genentech, Bayer, and Merck KGaA, focusing on oncology and immunology [4][10][13] - **Clinical Programs**: The company is actively developing several programs, including REC-1245 (RBM39) and REC-617 (CDK7), with ongoing trials aimed at identifying responsive patient populations [5][8][20] - **Financial Performance**: Total revenue for Q2 2025 was $19.2 million, up from $14.4 million in Q2 2024, while R&D expenses increased significantly to $128.6 million due to new collaborations and operational expansions [20][21] Pipeline Updates - **REC-1245 (RBM39)**: This potential first-in-class oral degrader is currently in a Phase 1/2 trial, targeting tumors with replication stress and DNA repair vulnerabilities [5][8] - **REC-617 (CDK7)**: The company initiated a combination dose escalation trial in platinum-resistant ovarian cancer, showing promising early safety and efficacy signals [8][20] - **Other Programs**: Additional programs like REC-102 for hypophosphatasia and REC-4881 for familial adenomatous polyposis are also in development, with various milestones expected in the coming years [8][20] Financial Position - As of June 30, 2025, Recursion had cash and cash equivalents of $533.8 million, down from $603.0 million at the end of 2024, indicating a strong cash runway into Q4 2027 [11][15] - The net loss for Q2 2025 was $171.9 million, compared to a net loss of $97.5 million in Q2 2024, primarily driven by increased R&D and G&A expenses [20][21]

Company Overview - Recursion is a clinical stage TechBio company focused on decoding biology to improve lives, utilizing a platform called Recursion OS that generates extensive biological and chemical datasets [3][4] - The company employs advanced machine-learning algorithms to analyze trillions of relationships in biology and chemistry, aiming to enhance drug discovery and development [3] Upcoming Earnings Call - Recursion will host a public earnings call on August 5, 2025, at 8:00 am ET, where it will provide business updates and report its second quarter 2025 financial results [1][2] - The earnings call will be accessible via live stream on Recursion's social media platforms, including X (formerly Twitter), LinkedIn, and YouTube, allowing investors and the public to submit questions [2]

Portfolio and Pipeline - Recursion has a streamlined, integrated portfolio strategy focused on near and long-term impact, leveraging the Recursion OS 2.0 platform to prioritize opportunities and exit underperforming efforts[21] - The company is advancing REC-617 (CDK7 inhibitor) into combination studies in 1H25 and expects additional Phase 1 data from ELUCIDATE in 2H25[33, 144] - REC-7735 (PI3Kα H1047R inhibitor) is expected to have a development candidate nomination in 2H25, with preclinical data showing superior in vivo efficacy compared to Alpelisib and Capivasertib[33, 87, 88, 144] - REV102 (ENPP1 inhibitor) is expected to initiate Phase 1 in 2H26, developed in partnership with Rallybio, with preclinical data showing restored bone density to wildtype levels in treated mice[33, 111, 114, 144] - Three clinical programs (REC-994, REC-2282, REC-3964) and one preclinical program (REC-4209) have been deprioritized as part of strategic portfolio prioritization[22, 27] Partnerships and Financials - Recursion has several partnerships, including an oncology and immunology collaboration with >$5 billion total value and a neuroscience and oncology partnership with up to $300 million per program for 40 programs[23] - As of March 31, 2025, Recursion had $5092 million in cash, with an expected cash runway until mid-2027[147] - The company anticipates ≤$450 million expected cash burn for FY2025, excluding potential partnership and financing inflows, achieved through pipeline prioritization and streamlined operations[150] Technology and Innovation - Recursion OS is central to the company's strategy, driving a data-led portfolio approach and enabling rapid validation of opportunities[9, 21, 31] - The company is focused on developing first-in-class and best-in-class molecules, leveraging its integrated, end-to-end tech stack and multimodal biology, design, and ClinTech capabilities[32] - Recursion's approach aims to reduce the time to candidate ID and cost to IND compared to industry legacy programs[18] REC-4881 (MEK1/2 Inhibitor) for FAP - REC-4881 is being developed as a chemoprevention for Familial Adenomatous Polyposis (FAP), targeting approximately 50000 addressable patients[28, 39] - Preliminary Phase 1b/2 data shows a 43% median reduction in total polyp burden at week 13 in efficacy evaluable patients on the 4 mg dose[68] - The program is currently enrolling, with additional efficacy and safety data expected in 2H25[38, 78]